Skip to main content
. 2008 Apr;10(4):303–313. doi: 10.1593/neo.07834

Figure 2.

Figure 2

Figure 2

Inhibitions of HDAC by LAQ824 are associated with a significant drop in tumor bioenergetics and increase in phosphomonoesters and phosphocholine levels. (A) In vitro 31P MRS of an HT29 cell extract treated with: vehicle (bottom panel), 34 µM SAHA (middle panel), and 350 nM LAQ824 (top panel) for 24 hours. Peak assignments: phosphocholine (PC), glycerophosphocholine (GPC), glycerophosphoethanolamine (GPE), inorganic phosphate (Pi), phosphocreatine (PCr), and nucleoside triphosphates (α-, β-, λ-NTP). (B) In vivo 31P MR spectra of a HT29 tumor before (top panel) and after (bottom panel) LAQ824 treatment (25 mg/kg i.p. for 2 days) are shown. Peak assignments: phosphomonoesters (PME), phosphodiesters (PDE), inorganic phosphate (Pi), phosphocreatine (PCr), and nucleoside triphosphates (α-, β-, λ-NTP). (C) In vitro 1H MR spectra of vehicle- (top panel) and LAQ824-treated (bottom panel) HT29 tumor extracts are illustrated. Peak assignments: leucine (1), iso-leucine (2), valine (3), lactate (4), alanine (5), acetate (6), glutamate (7), glutamine (8), dimethylamine (9), creatine + phosphocreatine (10), free choline (11), phosphocholine (12), glycerophosphocholine (13), taurine (14), glycine (15), creatine (16), phosphocreatine (17), water (18), glucose (19).